In this setting, it is likely that especially preoperative CEA serum concentrations might be integrated into predictive algorithms as a surrogate for different aspects regarding the CCA pathophysiology, rather than being used as “stand alone” marker which determines the patients ́ treatment. The gene discussed is CEACAM5; the disease is cholangiocarcinoma.